FY2029 Earnings Estimate for MNPR Issued By HC Wainwright

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Monopar Therapeutics in a research note issued to investors on Wednesday, January 22nd. HC Wainwright analyst S. Lee anticipates that the company will post earnings of $3.66 per share for the year. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share.

MNPR has been the topic of several other research reports. Rodman & Renshaw started coverage on shares of Monopar Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $50.00 price objective on the stock. Piper Sandler began coverage on Monopar Therapeutics in a research report on Friday, January 10th. They set an “overweight” rating and a $72.00 price target on the stock.

Monopar Therapeutics Stock Up 0.2 %

Shares of NASDAQ:MNPR traded up $0.08 during midday trading on Thursday, reaching $33.75. 8,137 shares of the company traded hands, compared to its average volume of 47,243. The firm’s fifty day moving average price is $23.76 and its two-hundred day moving average price is $12.15. The firm has a market capitalization of $205.84 million, a price-to-earnings ratio of -17.13 and a beta of 1.23. Monopar Therapeutics has a 12 month low of $1.54 and a 12 month high of $38.50.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.09.

Insider Buying and Selling

In related news, CFO Karthik Radhakrishnan acquired 1,550 shares of Monopar Therapeutics stock in a transaction dated Monday, October 28th. The stock was purchased at an average cost of $16.25 per share, for a total transaction of $25,187.50. Following the purchase, the chief financial officer now directly owns 1,550 shares of the company’s stock, valued at approximately $25,187.50. This trade represents a ? increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 34.90% of the stock is currently owned by corporate insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.